Biovitrum and Affibody seal collaboration

Collaboration

Swedish biotechs Biovitrum AB and Affibody have signed a collaboration agreement with the aim of developing therapies for inflammation and autoimmune diseases.

Biovitrum gains access to the proprietary technology platform of Affibody molecules and to an albumin-binding technology for pharmaceutical development. Affibody molecules are small stable proteins that can have the same effects as large proteins, and in addition have potential efficacy, safety, administration route and price benefits. The albumin-binding technology is designed to enhance the efficacy of biopharmaceuticals by extending their half-life.

The agreement involves a defined protein target and a product license agreement.